Targeting of diacerein loaded lipid nanoparticles to intra-articular cartilage using chondroitin sulfate as homing carrier for treatment of osteoarthritis in rats

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 5, 2014, Pages e1031-e1040

  Jain, Achint ^a,b   Mishra, Sandeep Kumar ^a   Vuddanda, Parameswara Rao ^a   Singh, Sanjay Kumar ^a   Singh, Royana ^c   Singh, Sanjay ^a  

^a BANARAS HINDU UNIVERSITY   (India)

^b National Institute of Pharmaceutical Education and Research (NIPER)   (India)

^c BANARAS HINDU UNIVERSITY   (India)

Author keywords

Articular cartilage; Chondroitin sulfate; Diacerein; Histopathology; Nanoparticles

Indexed keywords

BIOCHEMISTRY; CARTILAGE; CONTROLLED DRUG DELIVERY; FIGHTER AIRCRAFT; JOINTS (ANATOMY); NANOPARTICLES; SULFUR COMPOUNDS; TISSUE;

ARTICULAR CARTILAGES; CHONDROITIN SULFATES; DIACEREIN; DRUG CONCENTRATION; HISTOPATHOLOGY; LIPID NANOPARTICLES; SOLID LIPID NANOPARTICLE (SLN); SYSTEMIC TOXICITIES;

TARGETED DRUG DELIVERY;

CHONDROITIN SULFATE; DIACEREIN; DRUG CARRIER; POLYSACCHARIDE; RHEIN; ANTHRAQUINONE DERIVATIVE; LIPID; NANOPARTICLE; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; ARTICULAR CARTILAGE; BIOAVAILABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISPERSION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG TARGETING; FEMALE; FEMUR; JOINT; KNEE; KNEE OSTEOARTHRITIS; MALE; METABOLITE; NONHUMAN; PARTICLE SIZE; RAT; ANIMAL; CHEMISTRY; DRUG EFFECTS; OSTEOARTHRITIS;

RATTUS;

ANIMALS; ANTHRAQUINONES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARTILAGE, ARTICULAR; CHONDROITIN SULFATES; DRUG CARRIERS; FEMALE; LIPIDS; MALE; NANOPARTICLES; OSTEOARTHRITIS; RATS;

EID: 84903544678     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2014.01.008     Document Type: Article

References (41)

1. Lorenz H., Richter W. Osteoarthritis: cellular and molecular changes in degenerating cartilage. Prog Histochem Cytochem 2006, 40:135-163.
2. Alcaraz M.J., Megias J., Garcia-Arnandis I., Clerigues V., Guillen M.I. New molecular targets for the treatment of osteoarthritis. Biochem Pharmacol 2010, 80:13-21.
3. Kobayashi K., Imaizumi R., Sumichika H., Tanaka H., Goda M., Fukunari A., et al. Sodium iodoacetate-induced experimental osteoarthritis and associated pain model in rats. J Vet Med Sci 2003, 65:1195-1199.
4. Driban J.B., Sitler M.R., Barbe M.F., Balasubramanian E. Is osteoarthritis a heterogeneous disease that can be stratified into subsets?. Clin Rheumatol 2010, 29:123-131.
5. Myers S.L., Brandt K.D., Ehlich J.W., Braunstein E.M., Shelbourne K.D., Heck D.A., et al. Synovial inflammation in patients with early osteoarthritis of the knee. J Rheumatol 1990, 17:1662-1669.
6. Dougados M., Nguyen M., Berdah L., Mazieres B., Vignon E., Lequesne M. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the chondromodulating effect of diacerein in OA of the hip. Arthritis Rheum 2001, 44:2539-2547.
7. Mahajan A., Singh K., Tandon V.R., Kumar S., Kumar H. Diacerein: a new symptomatic slow acting drug for osteoarthritis. J Med Educ Res 2006, 8:173-175.
8. Deepak P., Ehrenpreis E.D. Diarrhea. Dis Mon: DM 2011, 57:490-510.
9. Wildi L.M., Raynauld J.P., Martel-Pelletier J., Beaulieu A., Bessette L., Morin F., et al. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. Ann Rheum Dis 2011, 70:982-989.
10. Lauder R.M. Chondroitin sulphate: a complex molecule with potential impacts on a wide range of biological systems. Complement Ther Med 2009, 17:56-62.
11. Monfort J., Pelletier J.P., Garcia-Giralt N., Martel-Pelletier J. Biochemical basis of the effect of chondroitin sulphate on osteoarthritis articular tissues. Ann Rheum Dis 2008, 67:735-740.
12. Bollet A.J., Nance J.L. Biochemical findings in normal and osteoarthritic articular cartilage. Chondroitin sulfate concentration and chain length, water, and ash content. J Clin Invest 1966, 45:1170-1177.
13. Reis A.V., Guilherme M.R., Mattoso L.H., Rubira A.F., Tambourgi E.B., Muniz E.C. Nanometer- and submicrometer-sized hollow spheres of chondroitin sulfate as a potential formulation strategy for anti-inflammatory encapsulation. Pharm Res 2009, 26:438-444.
14. Mehnert W., Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001, 47:165-196.
15. Jain A., Singh S.K., Singh Y., Singh S. Development of lipid nanoparticles of diacerein, an antiosteoarthritic drug for enhancement in bioavailability and reduction in its side effects. J Biomed Nanotechnol 2013, 9:891-900.
16. Joshi M., Pathak S., Sharma S., Patravale V. Design and in vivo pharmacodynamic evaluation of nanostructured lipid carriers for parenteral delivery of artemether: Nanoject. Int J Pharm 2008, 364:119-126.
17. Rawat M.K., Jain A., Singh S. Studies on binary lipid matrix based solid lipid nanoparticles of repaglinide: in vitro and in vivo evaluation. J Pharm Sci 2011, 100:2366-2378.
18. Holm R., Mullertz A., Christensen E., Hoy C.E., Kristensen H.G. Comparison of total oral bioavailability and the lymphatic transport of halofantrine from three different unsaturated triglycerides in lymph-cannulated conscious rats. Eur J Pharm Sci 2001, 14:331-337.
19. Singh S., Muthu M.S. Preparation and characterization of nanoparticles containing an atypical antipsychotic agent. Nanomedicine 2007, 2:233-240.
20. Dinser R. Animal models for arthritis. Best Pract Res Clin Rheumatol 2008, 22:253-267.
21. Silva A., Andersen M.L., Tufik S. Sleep pattern in an experimental model of osteoarthritis. Pain 2008, 140:446-455.
22. Lu Y., Zhang Y., Yang Z., Tang X. Formulation of an intravenous emulsion loaded with a clarithromycin-phospholipid complex and its pharmacokinetics in rats. Int J Pharm 2009, 366:160-169.
23. Tang W.F., Huang X., Yu Q., Qin F., Wan M.H., Wang Y.G., et al. Determination and pharmacokinetic comparison of rhein in rats after oral dosed with Da-Cheng-Qi decoction and Xiao-Cheng-Qi decoction. Biomed Chromatogr 2007, 21:1186-1190.
24. Lee J.H., Kim J.M., Kim C. Pharmacokinetic analysis of rhein in Rheum undulatum L. J Ethnopharmacol 2003, 84:5-9.
25. Ojha A., Rathod R., Padh H. Simultaneous HPLC-UV determination of rhein and aceclofenac in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877:1145-1148.
26. Levy A.S.A., Simon O., Shelly J., Gardener M. 6-Shogaol reduced chronic inflammatory response in the knees of rats treated with complete Freund's adjuvant. BMC Pharmacol 2006, 6:12.
27. Somashekar P.L., Tripathy A.S., Sathish K.P., Chandrashekar J., Palakshi G.O. Colorimetric estimation of chondroitin sulfate in bulk drug and pharmaceutical formulation using cationic dye methylene blue. Der Pharma Chemica 2010, 3:90-96.
28. Guzman R.E., Evans M.G., Bove S., Morenko B., Kilgore K. Mono-iodoacetate-induced histologic changes in subchondral bone and articular cartilage of rat femorotibial joints: an animal model of osteoarthritis. Toxicol Pathol 2003, 31:619-624.
29. Pritzker K.P., Gay S., Jimenez S.A., Ostergaard K., Pelletier J.P., Revell P.A., et al. Osteoarthritis cartilage histopathology: grading and staging. Osteoarthr Cartil 2006, 14:13-29.
30. Wu L., Zhang J., Watanabe W. Physical and chemical stability of drug nanoparticles. Adv Drug Deliv Rev 2011, 63:456-469.
31. Johnson W. Final report on the safety assessment of acetyl triethyl citrate, acetyl tributyl citrate, acetyl trihexyl citrate, and acetyl trioctyl citrate. Int J Toxicol 2002, 21(2):1-17.
32. Tran P.H., Tran T.T., Lee K.H., Kim D.J., Lee B.J. Dissolution-modulating mechanism of pH modifiers in solid dispersion containing weakly acidic or basic drugs with poor water solubility. Expert Opin Drug Deliv 2010, 7:647-661.
33. Cavalli R., Aquilano D., Carrlotti M.E., Gasco M.R. Study by X-ray powder diffraction and differential scanning calorimetry of two model drugs, phenothiazine and nifedipine, incorporated into lipid nanoparticles. Eur J Pharm Biopharm 1995, 41:329-333.
34. Bambagiotti-Alberti M., Bartolucci G., Bruni B., Coran S.A., Di Vaira M. Physico-chemical and structural characterization of diacerhein. J Pharm Biomed Anal 2009, 49:1065-1069.
35. Singh S., Dobhal A.K., Jain A., Pandit J.K., Chakraborty S. Formulation and evaluation of solid lipid nanoparticles of a water soluble drug: Zidovudine. Chem Pharm Bull 2010, 58:650-655.
36. Muthu M.S., Singh S. Studies on biodegradable polymeric nanoparticles of risperidone: in vitro and in vivo evaluation. Nanomedicine 2008, 3:305-319.
37. Muller R.H., Wallis K.H. Surface modification of i.v. injectable biodegradable nanoparticles with poloxamer polymers and poloxamine 908. Int J Pharm 1993, 89:25-31.
38. Washington C. Drug release from microdisperse systems: a critical review. Int J Pharm 1990, 58:1-12.
39. Venkatesan N., Uchino K., Amagase K., Ito Y., Shibata N., Takada K. Gastro-intestinal patch system for the delivery of erythropoietin. J Control Release 2006, 111:19-26.
40. Song K.H., Chung S.J., Shim C.K. Enhanced intestinal absorption of salmon calcitonin (sCT) from proliposomes containing bile salts. J Control Release 2005, 106:298-308.
41. O'Driscoll C.M. Lipid-based formulations for intestinal lymphatic delivery. Eur J Pharm Sci 2002, 15:405-415.